Hepatocellular carcinoma with extrahepatic metastasis: Are there still candidates for transarterial chemoembolization as an initial treatment?

• Published in: PloS one Vol. 14; no. 3; p. e0213547
• Main Authors: Kim, Jihye, Sinn, Dong-Hyun, Choi, Moon Seok, Kang, Wonseok, Gwak, Geum-Youn, Paik, Yong-Han, Lee, Joon Hyeok, Koh, Kwang Cheol, Paik, Seung Woon
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 07.03.2019; Public Library of Science (PLoS)
• Subjects: Aged; Biology and Life Sciences; Cancer; Cancer metastasis; Cancer patients; Carcinoma; Carcinoma, Hepatocellular - mortality; Carcinoma, Hepatocellular - pathology; Carcinoma, Hepatocellular - therapy; Chemoembolization, Therapeutic; Development and progression; Disease-Free Survival; Dosage and administration; Drug therapy; Female; Follow-Up Studies; Health aspects; Hepatitis B; Hepatitis B virus; Hepatocellular carcinoma; Humans; Liver Neoplasms - mortality; Liver Neoplasms - pathology; Liver Neoplasms - therapy; Male; Medical research; Medicine and Health Sciences; Middle Aged; Mortality; Neoplasm Metastasis; Patient outcomes; Prognosis; Registries; Retrospective Studies; Sorafenib; Sorafenib - administration & dosage; Survival Rate; Tumors
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0213547

Currently, sorafenib is indicated for hepatocellular carcinoma (HCC) with extrahepatic metastasis (EHM), and many other systemic agents are becoming available. However, a few HCC patients with EHM still undergo transarterial chemoembolization (TACE) for intrahepatic tumor control. We aimed to investigate whether TACE is appropriate for patients with EHM, and if so, which subgroup may benefit from TACE. A total of 186 consecutive HCC patients (median: 55 years, male: 86.0%, hepatitis B virus: 81.7%, Child-Pugh Class A: 83.3%) with EHM (nodal metastasis: 60.8%, distant metastasis: 39.2%) between 2010 and 2014 were analyzed. Initial treatment included sorafenib in 69 patients, and TACE in 117 patients. During a median follow-up of 6.6 months (range: 0.2-94.6 months), mortality was observed in 90.3% (168/186). The median survival was better for patients who received TACE than those treated with sorafenib (8.2 months vs. 4.6 months, p < 0.001). However, baseline characteristics varied between patients initially treated with TACE and sorafenib, and the treatment modality was not an independent factor associated with overall survival (hazard ratio: 1.19, 95% confidence interval: 0.81-1.75, p = 0.36). In sub-group analysis, TACE was associated with better survival only among younger patients and those with segmental/lobar portal vein invasion. In HCC patients with EHM, TACE was not an independent favorable prognostic factor compared to sorafenib. The concept of intrahepatic control in HCC patients with EHM may need to be reevaluated in the era of promising systemic therapies, although there can be specific subgroups who still benefit from TACE.